Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIRMISH R SHAH

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1033113899
CMS profile
1752
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$122,434.65

79 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIRMISH R SHAH

NPI 1033113899 · CMS profile ID 1752

Allopathic & Osteopathic Physicians / Internal Medicine

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033113899?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIRMISH R SHAH, NPI 1033113899, CMS profile ID 1752. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033113899?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). NIRMISH R SHAH, NPI 1033113899, CMS profile ID 1752. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033113899?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
NIRMISH R SHAH, NPI 1033113899, CMS profile ID 1752, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1033113899?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

79 matching records · $122,434.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 79 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–79 of 79.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Global Blood Therapeutics, Inc. $1,850.0006/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341977 CMS
Novartis Pharmaceuticals Corporation $3,050.0006/14/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813250471 CMS
Global Blood Therapeutics, Inc. $1,850.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341975 CMS
Global Blood Therapeutics, Inc. $7,722.8606/02/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341973 CMS
Alexion Pharmaceuticals, Inc. $900.0005/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783127177 CMS
Global Blood Therapeutics, Inc. $2,120.0005/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341971 CMS
Global Blood Therapeutics, Inc. $1,850.0005/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341969 CMS
Global Blood Therapeutics, Inc. $1,850.0004/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341967 CMS
Novartis Pharmaceuticals Corporation $2,440.0004/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813250455 CMS
Global Blood Therapeutics, Inc. $1,850.0004/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341965 CMS
Emmaus Medical, Inc. $1,500.0004/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850492621 CMS
Novo Nordisk Inc $1,360.0004/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810643607 CMS
Global Blood Therapeutics, Inc. $1,850.0004/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341963 CMS
Global Blood Therapeutics, Inc. $462.5004/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341961 CMS
Global Blood Therapeutics, Inc. $6,012.5004/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341957 CMS
Global Blood Therapeutics, Inc. $36.6204/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341959 CMS
Global Blood Therapeutics, Inc. $1,850.0003/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341953 CMS
Global Blood Therapeutics, Inc. $1,850.0003/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341955 CMS
Global Blood Therapeutics, Inc. $1,850.0003/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341951 CMS
Global Blood Therapeutics, Inc. $1,850.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341949 CMS
Global Blood Therapeutics, Inc. $1,850.0003/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341947 CMS
Global Blood Therapeutics, Inc. $1,850.0002/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341945 CMS
Global Blood Therapeutics, Inc. $1,850.0002/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341943 CMS
Global Blood Therapeutics, Inc. $1,387.5002/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341939 CMS
Global Blood Therapeutics, Inc. $1,850.0002/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341941 CMS
Global Blood Therapeutics, Inc. $4,625.0002/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341937 CMS
Global Blood Therapeutics, Inc. $1,850.0002/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341935 CMS
Global Blood Therapeutics, Inc. $1,850.0001/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341933 CMS
Novartis Pharmaceuticals Corporation $1,220.0001/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813250451 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $133,632.01 119
PY2020 $104,451.77 62
PY2021 $122,434.65 79
PY2022 $157,067.57 97
PY2023 $131,118.13 92
PY2024 $162,751.83 126
PY2025 $50,360.30 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $51,784.80 25
PY2025 Principal investigator $104,029.19 13
PY2024 Recipient $31,560.00 13
PY2024 Principal investigator $135,912.97 10
PY2023 Recipient $24,310.00 12
PY2023 Principal investigator $171,773.81 13
PY2022 Principal investigator $113,965.75 20
PY2021 Principal investigator $233,839.47 35
PY2020 Recipient $5,000.00 3
PY2020 Principal investigator $79,870.05 22
PY2019 Recipient $32,273.52 24
PY2019 Principal investigator $125,486.36 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Agios Pharmaceuticals, Inc. $577.50 12/19/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217048
Recipient Agios Pharmaceuticals, Inc. $5,850.00 12/05/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217038
Recipient Agios Pharmaceuticals, Inc. $1,155.00 11/20/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217118
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $4,100.00 11/12/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228720075
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $3,901.70 11/12/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228734174
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $36.00 11/12/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228734873
Recipient PFIZER INC. $3,200.00 11/04/2025 Covered Recipient Physician VOXELOTOR CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727887
Recipient PFIZER INC. $3,200.00 10/31/2025 Covered Recipient Physician VOXELOTOR CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727115
Recipient SANOFI US SERVICES INC. $9.89 10/27/2025 Covered Recipient Physician A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226125369
Recipient SANOFI US SERVICES INC. $29.56 10/27/2025 Covered Recipient Physician A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226125373
Recipient SANOFI US SERVICES INC. $7.70 10/27/2025 Covered Recipient Physician A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226125377
Recipient Agios Pharmaceuticals, Inc. $2,155.00 10/23/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217036
Recipient SANOFI US SERVICES INC. $293.17 10/15/2025 Covered Recipient Physician A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226125350
Recipient SANOFI US SERVICES INC. $149.06 10/15/2025 Covered Recipient Physician A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226125354
Recipient SANOFI US SERVICES INC. $346.54 10/15/2025 Covered Recipient Physician A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226125382
Recipient SANOFI US SERVICES INC. $67.81 10/14/2025 Covered Recipient Physician A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226125359
Recipient SANOFI US SERVICES INC. $93.35 10/14/2025 Covered Recipient Physician A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226125363
Recipient SANOFI US SERVICES INC. $60.22 10/14/2025 Covered Recipient Physician A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226125366
Principal investigator 1 PFIZER INC. $17,500.00 09/26/2025 Non-covered Recipient Entity
Duke University
A PHASE 23 RANDOMIZED MULTICENTER STUDY OF GBT021601 ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE AND AN OPENLABEL PHARMACOKINETICS STUDY IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 1228723548
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $33,000.00 09/24/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228724306
Recipient Agios Pharmaceuticals, Inc. $4,042.50 09/18/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217074
Recipient Agios Pharmaceuticals, Inc. $4,080.00 08/21/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217062
Recipient Agios Pharmaceuticals, Inc. $2,502.50 08/07/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217116
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $17,053.24 08/01/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228742746
Recipient Agios Pharmaceuticals, Inc. $1,347.50 07/24/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217046
Recipient PFIZER INC. $330.00 06/16/2025 Covered Recipient Physician INCLACUMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769507
Recipient Agios Pharmaceuticals, Inc. $4,657.50 05/22/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217100
Recipient Agios Pharmaceuticals, Inc. $5,427.50 04/24/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217114
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $4,750.00 04/16/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228774521
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $144.00 04/16/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228774560
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $750.00 04/16/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228775281
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $1,000.00 04/16/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228775406
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $360.00 04/16/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228775465
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $786.00 04/16/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228776451
Recipient Agios Pharmaceuticals, Inc. $6,582.50 03/27/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217098
Recipient Agios Pharmaceuticals, Inc. $2,732.50 02/20/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217060
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $20,648.25 02/19/2025 Non-covered Recipient Entity
Duke University
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228764907
Recipient Agios Pharmaceuticals, Inc. $2,887.50 01/23/2025 Covered Recipient Physician A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease No dispute reported 06/30/2026 1250217072